|View printer-friendly version|
Spring Bank Announces Presentation of Promising Results from Study Highlighting Immune-Activation with Inarigivir 400mg
The results from this study demonstrate that, across all patients, inarigivir rapidly increased activation markers of innate immunity on circulating peripheral monocytes and dendritic cells, which was sustained over a ten-day period of dosing without evidence of tolerance. “Key opinion leaders in the field of hepatitis B treatment believe that re-activation of the chronic HBV patient’s immune system will be required to achieve a significant elevation in HBV functional cure rates,” said
In addition, the forward-looking statements included in this press release represent Spring Bank’s views as of the date hereof.
Source: Spring Bank Pharmaceuticals, Inc.